Trial Profile
A randomized phase 2 study of irinotecan plus cetuximab with or without enzastaurin in patients with recurrent colorectal cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Enzastaurin (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Jun 2010 Results presented at 12th World Congress on Gastrointestinal Cancer 2010.
- 26 May 2009 Actual patient number (26) and actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
- 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.